aurora 2 is related to lymph node metastasis in colon and gastric carcinoma
aurora 2 is related to lymph node metastasis in colon and gastric carcinoma
批准号:
12671232
负责人:
SADANAGA Noriaki
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Backgrounds: Aurora2 is a family of human serine/threonine kinases characterized as cell cycle regulators. In this study, we evaluated the expression of aurora 2 mRNA in gastro-intestinal carcinoma and the correlation between overexpression and clinico-pathological factors. Material and methods: We studied the 201 Japanese patients with carcinoma of gastrointestinal tract, including 53 esophageal cancer, 72 gastric cancer and 76 colorectal cancer. The expression of aurora 2 was investigated by RT-PCR. Results: Aurora 2 mRNA was expressed in 27 of 53 (51%) esophageal cancer, 38 of 72 (53%) gastric cancer and 36 of 76 (46%) colorectal cancer. The relations between the aurora2 expression and the clinicopathological factors was examined. In gastric carcinoma, lymph node metastasis was shown in 27 of 38 (71%) cases with aurora2 expression positive group, more frequent than those with negative expression (p<0.01). In colon carcinoma, lymph node metastasis was present in 23 of 36 (64%) cases with expression positive group and in 7 of 40 (18%) without, a statistically significant difference (p<0.01). There was lymphatic vessel invasion in 25 of 36 (69%) in the aurora2 expression positive group but in only 12 of 40 (30%) in the negative group (p<0.01). There was a significant differences between the two groups in Dukes classification (p<0.01). The overall 5-year survival rate for patients with aurora2 overexpression was lower than for patients without expression in colorectal cancer (92% vs. 64%, p<0.05). Conclusions: These results suggested that aurora2 expression was associated with tumor progression and patients survival and may be a new prognostic indicator for patients with colon carcinoma.
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Mori M.et al.: "Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma"Cancer Res. 61. 7379-7382 (2001)
Mori M.等人:“Msh2 蛋白表达的缺失与结直肠癌中 FHIT 位点和 Fhit 蛋白表达的改变有关”Cancer Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Tahara K. et al.: "MAGE-specific cytotoxic T lymphocytes require non-specific CD54 adherence receptors on carcinoma cells."Int J Oncol. 17. 805-810 (2000)
Tahara K. 等人:“MAGE 特异性细胞毒性 T 淋巴细胞需要癌细胞上的非特异性 CD54 粘附受体。”Int J Oncol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kataoka A. et al.: "RT-PCR detection of breast cancer cells in sentinellymph nodes."Int J Oncol. 16. 1147-1152 (2000)
Kataoka A. 等人:“RT-PCR 检测前哨淋巴结中的乳腺癌细胞。”Int J Oncol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Mori M et al.: "Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus"Cancer Res.. 60・5. 1177-1182 (2000)
Mori M等:“食管癌和癌前病变中Fhit的表达改变”Cancer Res. 1177-1182 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Mori M et al: "Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus."Cancer Res. 60. 1177-1182 (2000)
Mori M 等人:“食管癌和癌前病变中 Fhit 的表达发生改变。”Cancer Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 20 条
New Molecular target of cancer cell migration in breast cancer patients.
-
批准号:19591510
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:SADANAGA Noriaki
-
依托单位:
pH regulating therapy for hepatocellular carcinoma
-
批准号:10671199
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:SADANAGA Noriaki
-
依托单位:
海外基金